Molecular Partners Ag Stock Performance
| MOLN Stock | USD 4.73 0.02 0.42% |
On a scale of 0 to 100, Molecular Partners holds a performance score of 8. The company secures a Beta (Market Risk) of 0.65, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Molecular Partners' returns are expected to increase less than the market. However, during the bear market, the loss of holding Molecular Partners is expected to be smaller as well. Please check Molecular Partners' treynor ratio, as well as the relationship between the semi variance and day median price , to make a quick decision on whether Molecular Partners' current price movements will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Molecular Partners AG are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of very unsteady essential indicators, Molecular Partners displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.42) | Five Day Return 6.29 | Year To Date Return 12.09 | Ten Year Return (75.93) | All Time Return (75.93) |
1 | Will Molecular Partners AG stock beat revenue estimates - 2025 Major Catalysts Fast Gain Stock Tips - Newser | 12/01/2025 |
2 | Molecular Partners Presents Promising MP0533 Trial Data at ASH Meeting - TipRanks | 12/08/2025 |
3 | Molecular Partners to Present at 44th Annual J.P. Morgan Healthcare Conference | 12/18/2025 |
4 | Hemadri Cements Limited Tests 50 Day MA After Sharp Decline - Dividend Reinvestment Plans Low Risk Trading Alerts - Bollywood Helpline | 12/22/2025 |
5 | Minnesota Organization of Leaders in Nursing Partners with the Virtual Nursing Academy to Strengthen Virtual Care Leadership Statewide | 01/26/2026 |
6 | Brokers Offer Predictions for MOLN FY2025 Earnings | 01/29/2026 |
7 | Molecular Partners Highlights Favorable MP0712 DLL3 Radiotherapeutic Imaging, U.S. Phase III Ready | 02/03/2026 |
| Begin Period Cash Flow | 67.3 M | |
| Total Cashflows From Investing Activities | 40.5 M |
Molecular | Build AI portfolio with Molecular Stock |
Molecular Partners Relative Risk vs. Return Landscape
If you would invest 404.00 in Molecular Partners AG on November 21, 2025 and sell it today you would earn a total of 69.00 from holding Molecular Partners AG or generate 17.08% return on investment over 90 days. Molecular Partners AG is currently generating 0.311% in daily expected returns and assumes 2.9761% risk (volatility on return distribution) over the 90 days horizon. In different words, 26% of stocks are less volatile than Molecular, and 94% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Molecular Partners Target Price Odds to finish over Current Price
The tendency of Molecular Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 4.73 | 90 days | 4.73 | roughly 2.03 |
Based on a normal probability distribution, the odds of Molecular Partners to move above the current price in 90 days from now is roughly 2.03 (This Molecular Partners AG probability density function shows the probability of Molecular Stock to fall within a particular range of prices over 90 days) .
Molecular Partners Price Density |
| Price |
Predictive Modules for Molecular Partners
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Molecular Partners. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Molecular Partners Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Molecular Partners is not an exception. The market had few large corrections towards the Molecular Partners' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Molecular Partners AG, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Molecular Partners within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.21 | |
β | Beta against Dow Jones | 0.65 | |
σ | Overall volatility | 0.21 | |
Ir | Information ratio | 0.07 |
Molecular Partners Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Molecular Partners for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Molecular Partners can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 4.97 M. Net Loss for the year was (54.04 M) with loss before overhead, payroll, taxes, and interest of (40.4 M). | |
| Molecular Partners AG currently holds about 267.13 M in cash with (59.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from thelincolnianonline.com: Molecular Partners Highlights Favorable MP0712 DLL3 Radiotherapeutic Imaging, U.S. Phase III Ready |
Molecular Partners Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Molecular Stock often depends not only on the future outlook of the current and potential Molecular Partners' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Molecular Partners' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 34 M | |
| Cash And Short Term Investments | 149.4 M |
Molecular Partners Fundamentals Growth
Molecular Stock prices reflect investors' perceptions of the future prospects and financial health of Molecular Partners, and Molecular Partners fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Molecular Stock performance.
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | 31.89 M | ||||
| Shares Outstanding | 37.4 M | ||||
| Price To Earning | 1.85 X | ||||
| Price To Book | 1.39 X | ||||
| Price To Sales | 199.56 X | ||||
| Revenue | 4.97 M | ||||
| Gross Profit | (40.4 M) | ||||
| EBITDA | (51.65 M) | ||||
| Net Income | (54.04 M) | ||||
| Cash And Equivalents | 267.13 M | ||||
| Cash Per Share | 8.22 X | ||||
| Total Debt | 2.44 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 14.37 X | ||||
| Book Value Per Share | 3.32 X | ||||
| Cash Flow From Operations | (59.25 M) | ||||
| Earnings Per Share | (2.10) X | ||||
| Market Capitalization | 177.65 M | ||||
| Total Asset | 158.53 M | ||||
| Retained Earnings | (246.29 M) | ||||
| Working Capital | 143.5 M | ||||
About Molecular Partners Performance
By examining Molecular Partners' fundamental ratios, stakeholders can obtain critical insights into Molecular Partners' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Molecular Partners is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.39) | (0.37) | |
| Return On Capital Employed | (0.48) | (0.45) | |
| Return On Assets | (0.39) | (0.37) | |
| Return On Equity | (0.44) | (0.46) |
Things to note about Molecular Partners performance evaluation
Checking the ongoing alerts about Molecular Partners for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Molecular Partners help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 4.97 M. Net Loss for the year was (54.04 M) with loss before overhead, payroll, taxes, and interest of (40.4 M). | |
| Molecular Partners AG currently holds about 267.13 M in cash with (59.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from thelincolnianonline.com: Molecular Partners Highlights Favorable MP0712 DLL3 Radiotherapeutic Imaging, U.S. Phase III Ready |
- Analyzing Molecular Partners' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Molecular Partners' stock is overvalued or undervalued compared to its peers.
- Examining Molecular Partners' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Molecular Partners' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Molecular Partners' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Molecular Partners' stock. These opinions can provide insight into Molecular Partners' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Will Biotechnology sector continue expanding? Could Molecular diversify its offerings? Factors like these will boost the valuation of Molecular Partners. Expected growth trajectory for Molecular significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Molecular Partners data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Molecular Partners' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Molecular Partners represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Molecular Partners' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.